MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration.
$12.90-0.54%
报价 2026-11-13
市值
$166.5M
EV
$187.3M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -33.4%
$11.85$19.37
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MDWDMediWound Ltd. | $166.5M | -0.5% | – | 19.2% | – | – | – | |
| BBOTBridgeBio Oncology Therapeutics Inc. | $171.7M | -8.9% | – | 0% | – | – | – | |
| IVVDInvivyd, Inc. | $171.6M | +2.6% | +64.0% | 91.4% | – | – | – | |
| ADCTADC Therapeutics S.A. | $171.1M | -5.0% | – | 88.8% | – | – | – | |
| YARWYarrow Bioscience Inc | $170.2M | -8.2% | – | 97.5% | – | – | – | |
| ZNTLZentalis Pharmaceuticals, Inc. | $167.1M | +1.2% | -22.2% | 0% | – | – | – | |
| NAGENiagen Bioscience Inc | $163.5M | -3.3% | +11.8% | 63.9% | 17.4x | 15.1x | 39.4x | |
| STROSutro Biopharma, Inc. | $163M | +2.4% | -66.8% | 97.2% | – | – | – | |
| RNAAvidity Biosciences, Inc. | $162M | +0.1% | -61.9% | 100% | – | – | – | |
| 同行中位数 | – | – | -22.2% | 90.1% | 17.4x | 15.1x | 39.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。